


M.-A. KASPER, A. STENGL, P. OCHTROP, M. GERLACH, T. STOSCHEK, D. SCHUMACHER, J. HELMA, M. PENKERT, E. KRAUSE, H. LEONHARDT*, C. P. R. HACKENBERGER* (LEIBNIZ-FORSCHUNGSINSTITUT FÜR MOLEKULARE PHARMAKOLOGIE, BERLIN, HUMBOLDT UNIVERSITÄT ZU BERLIN, AND LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN, GERMANY)

Ethynylphosphonamidates for the Rapid and Cysteine-Selective Generation of Efficacious Antibody–Drug Conjugates
Angew. Chem. Int. Ed. **2019**, *58*, 11631–11636.

Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates



Significance: Antibody–drug conjugates (ADCs) have emerged as a new class of targeted therapeutics. They combine the high potency of cytotoxic drugs with the tumor specificity of monoclonal antibodies. However, the insufficient stability in serum and undesired aggregation often lead to off-target toxicity.

Comment: The researchers report the conjugation of antimetabolic agent monomethyl auristatin F (MMAF) to the Her2-targeting antibody trastuzumab by using ethynylphosphonamidate functionalized linker B. The resulting ADC showed a drug-to-antibody ratio of 4.6. Furthermore, the use of a phosphonamidate linker bearing diethyleneglycol improved the polarity of the whole linker system. The ADCs had in vivo antitumor activity.

SYNFACTS Contributors: Dirk Trauner, Andrej Shemet
Synfacts 2019, 15(10), 1189 Published online: 17.09.2019
DOI: 10.1055/s-0039-1690935; Reg-No.: T08619SF

© 2019, Thieme. All rights reserved.
Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany

Category

Chemistry in
Medicine and
Biology

Key words

antibodies
bioconjugation
drug delivery

Synfact
of the
Month

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.